glp 1 agonist shortage The GLP-1 receptor shortage: What you need to know and do GLP-1 Agonists Market Report 2025-2033,

Description

Across the trials, ARD values ranged from + 0.6% to + 17%

J Periodontal Res 54:106114 [DOI] [PubMed] [Google Scholar] 51.Zhai S, Liu C, Vimalraj S, Subramanian R, Abullais SS, Arora S, Saravanan S (2023) Glucagon-like peptide-1 receptor promotes osteoblast differentiation of dental pulp stem cells and bone formation in a zebrafish scale regeneration model

53.Linnebjerg H, Kothare PA, Park S, et al

However, their use must be implemented thoughtfully, with careful attention to both the opportunities they provide and the challenges they present

In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: Injectable GLP-1s 2025 Ozempic for T2DM and peripheral artery disease (PAD) 2H 2025 Wegovy for heart failure with preserved ejection fraction (HFpEF) and obesity Oral GLP-1s October 2025 new indication for oral Rybelsus for secondary CV risk reduction 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape